Hemab Therapeutics (NASDAQ:COAG) Now Covered by Analysts at Rodman & Renshaw

Investment analysts at Rodman & Renshaw started coverage on shares of Hemab Therapeutics (NASDAQ:COAG) in a research note issued on Monday, Marketbeat.com reports. The brokerage set a “buy” rating and a $56.00 price target on the stock. Rodman & Renshaw’s price objective indicates a potential upside of 78.46% from the stock’s current price.

A number of other brokerages have also recently commented on COAG. Wedbush raised their target price on Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Weiss Ratings cut shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 25th. HC Wainwright raised their price objective on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group lifted their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $54.71.

Hemab Therapeutics Stock Up 5.3%

NASDAQ:COAG opened at $31.38 on Monday. Hemab Therapeutics has a 52 week low of $23.00 and a 52 week high of $55.42. The stock’s fifty day moving average price is $41.66. The firm has a market capitalization of $1.47 billion and a PE ratio of -1.27.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, equities analysts predict that Hemab Therapeutics will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Hemab Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new position in Hemab Therapeutics during the 2nd quarter worth approximately $230,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Hemab Therapeutics in the 2nd quarter valued at $688,000. Opaleye Management Inc. purchased a new stake in shares of Hemab Therapeutics during the 2nd quarter worth $1,750,000. State Street Corp purchased a new stake in shares of Hemab Therapeutics during the 2nd quarter worth $2,825,000. Finally, Braidwell LP acquired a new position in shares of Hemab Therapeutics during the second quarter worth $5,877,000.

About Hemab Therapeutics

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.